Department of Molecular Pathology, Pathology and Laboratory Medicine Institute, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH 44195, USA.
Arch Pathol Lab Med. 2011 May;135(5):544-57. doi: 10.5858/2010-0734-RAIR.1.
Adenocarcinoma of the breast is the most frequent cancer affecting women in both developed and developing regions of the world. From the moment of clinical presentation until the time of pathologic diagnosis, patients affected by this disease will face daunting questions related to prognosis and treatment options. While improvements in targeted therapies have led to increased patient survival, these same advances have created the imperative to accurately stratify patients to achieve maximum therapeutic efficacy while minimizing side effects. In this evolving era of personalized medicine, there is an ever-increasing need to overcome the limitations of traditional diagnostic practice.
To summarize the molecular diagnostics traditionally used to guide prognostication and treatment of breast carcinomas, to highlight published data on the molecular classification of these tumors, and to showcase molecular assays that will supplement traditional methods of categorizing the disease.
A review of the literature covering the molecular diagnostics of breast carcinomas with a focus on the gene expression and array studies used to characterize the molecular signatures of the disease. Special emphasis is placed on summarizing evolving technologies useful in the diagnosis and characterization of breast carcinoma.
Available and emerging molecular resources will allow pathologists to provide superior diagnostic, prognostic, and predictive information about individual breast carcinomas. These advances should translate into earlier identification and tailored therapy and should ultimately improve outcome for patients affected by this disease.
乳腺癌是全世界发达和发展中地区女性最常见的癌症。从临床表现到病理诊断,患有这种疾病的患者将面临与预后和治疗选择相关的艰巨问题。虽然靶向治疗的进步导致了患者生存率的提高,但这些同样的进步也要求我们必须准确地对患者进行分层,以实现最大的治疗效果,同时最小化副作用。在这个个体化医学的不断发展的时代,克服传统诊断实践的局限性的需求日益增加。
总结传统上用于指导乳腺癌预后和治疗的分子诊断方法,强调关于这些肿瘤的分子分类的已发表数据,并展示将补充传统疾病分类方法的分子检测。
对涵盖乳腺癌分子诊断的文献进行综述,重点是用于描述疾病分子特征的基因表达和阵列研究。特别强调总结有助于诊断和表征乳腺癌的不断发展的技术。
现有的和新兴的分子资源将使病理学家能够提供有关个体乳腺癌的卓越诊断、预后和预测信息。这些进展应该转化为更早的识别和针对性治疗,并最终改善患有这种疾病的患者的结局。